Nintedanib for Idiopathic Pulmonary Fibrosis

Abstract

Objective:

To review the pharmacology, safety, and efficacy of nintedanib for the treatment of idiopathic pulmonary fibrosis (IPF).

Methods:

A literature search was conducted via PubMed using the MeSH term “idiopathic pulmonary fibrosis” combined with the key word “nintedanib.” Additional online searches using Google Scholar, Micromedex, and PubMed were performed to obtain prescribing and cost information.

Results:

One phase II and 2 replicate phase III clinical trials that examined the safety and efficacy of nintedanib for IPF were identified. In patients with IPF, nintedanib was more effective than placebo in slowing the annual rate of decline in forced vital capacity (FVC). Improvements in mortality, quality of life, and risk of acute exacerbations have not been consistently demonstrated in clinical trials. Diarrhea was the most common adverse effect associated with nintedanib use. Outside of these clinical trials, there are limited data evaluating nintedanib for the treatment of IPF.

Conclusions:

Nintedanib is a safe and effective treatment option for patients with IPF. Nintedanib slows IPF disease progression by reducing the rate of decline in FVC. Reductions in mortality and acute exacerbations may be present in certain subgroups of patients, but these outcomes require further research. Future studies on nintedanib are needed to explore its use in more advanced stages of IPF, its long-term safety and efficacy, its value in combination with pirfenidone or other therapies for IPF, and its cost-effectiveness in clinical practice.

Keywords

nintedanib idiopathic pulmonary fibrosis

Get full access to this article

View all access options for this article.

References

Raimundo

Chang

Broder

. Clinical and economic burden of idiopathic pulmonary fibrosis: a retrospective cohort study. BMC Pulm Med. 2016;16(1):2. doi:10.1186/s12890-015-0165-1.

Lee

Mira-Avendano

Ryu

. The burden of idiopathic pulmonary fibrosis: an unmet public health need. Respir Med. 2014;108(7):955–967. doi:10.1016/j.rmed.2014.03.015.

Kistler

Nalysnyk

Rotella

. Lung transplantation in idiopathic pulmonary fibrosis: a systematic review of the literature. BMC Pulm Med. 2014;14(1):139. doi:10.1186/1471-2466-14-139.

OFEV (nintedanib). Prescribing Information. 2014. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205832s000lbl.pdf. Accessed June 1, 2017.

FDA News Release 2014. FDA approves Ofev to treat idiopathic pulmonary fibrosis. https://www.boehringer-ingelheim.us/press-release/fda-approves-boehringer-ingelheims-ofev-nintedanib-first-kinase-inhibitor-treat. Accessed December 1, 2015.

Richeldi

Costabel

Selman

. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med. 2011;365(12):1079–1087. doi:10.1056/nejmoa1103690.

Richeldi

Du bois

Raghu

. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2071–2082.

Raghu

Rochwerg

Zhang

. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: treatment of idiopathic pulmonary fibrosis. An Update of the 2011 Clinical Practice Guideline. Am J Respir Crit Care Med. 2015;192(2):e3–e19. doi:10.1164/rccm.201506-1063st.

Ferreira

. Two New IPF Treatments reportedly will cost between $94 K and $96 K a Year. 2014. http://pulmonaryfibrosisnews.com/2014/10/23/two-new-ipf-treatments-reportedly-will-cost-94k-96k-year/. Accessed December 1, 2015.

10.

Roth

Binder

Colbatzky

. Nintedanib: from discovery to the clinic. J Med Chem. 2015;58(3):1053–1063.

11.

Roth

Heckel

Colbatzky

. Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120). J Med Chem. 2009;52(14):4466–4480.

12.

Raghu

Collard

Egan

. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183(6):788–824, 2011. doi:10.1164/rccm.2009-040GL.

13.

Suissa

Ernst

. The INPULSIS enigma: exacerbations in idiopathic pulmonary fibrosis. Thorax. 2015;70(5):508–510. doi:10.1136/thoraxjnl-2014-206598.

14.

Costabel

Inoue

Richeldi

. Efficacy of nintedanib in idiopathic pulmonary fibrosis across prespecified subgroups in INPULSIS. Am J Respir Crit Care Med. 2016;193(2):178–185. doi: 10.1164/rccm.201503-0562OC. PubMed PMID: 26393389.

15.

Natsuizaka

Chiba

Kuronuma

. Epidemiologic Survey of Japanese Patients with Idiopathic Pulmonary Fibrosis and Investigation of Ethnic Differences. Am J Respir Crit Care Med. 2014;190(7):773–779.

16.

Horimasu

Ohshimo

Bonella

. MUC5B promoter polymorphism in Japanese patients with idiopathic pulmonary fibrosis. Respirology. 2015;20( 3):439–444. doi:10.1111/resp.12466.

17.

Taniguchi

Azuma

. Subgroup analysis of Asian patients in the INPULSIS® trials of nintedanib in idiopathic pulmonary fibrosis. Respirology. 2016;21(8):1425–1430. doi:10.1111/resp.12852.

18.

Azuma

Taniguchi

Inoue

. Nintedanib in Japanese patients with idiopathic pulmonary fibrosis: a subgroup analysis of the INPULSIS randomized trials. Respirology. 2017;22(4):750–757. doi:10.1111/resp.12960.

19.

Peljto

Zhang

Fingerlin

. Association between the MUC5B promoter polymorphism and survival in patients with idiopathic pulmonary fibrosis. JAMA. 2013;309(21):2232–2239. doi:10.1001/jama.2013.5827.

20.

Raghu

Wells

Nicholson

. Effect of nintedanib in subgroups of idiopathic pulmonary fibrosis by diagnostic criteria. Am J Respir Crit Care Med. 2017;195(1):78–85. doi:10.1164/rccm.201602-0402oc.

21.

Richeldi

Cottin

Bois

RMD

. Nintedanib in patients with idiopathic pulmonary fibrosis: Combined evidence from the TOMORROW and INPULSIS® trials. Respir Med. 2016;113:74–79. doi:10.1016/j.rmed.2016.02.001.

22.

Corte

Bonella

Crestani

. Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosis. Respir Res. 2015;16(1):116. doi:10.1186/s12931-015-0276-5.

23.

Wuyts

Kolb

Stowasser

. First data on efficacy and safety of nintedanib in patients with idiopathic pulmonary fibrosis and forced vital capacity of ≤50% of predicted value. Lung. 2016;194(5):739–743. doi:10.1007/s00408-016-9912-1.

24.

Canestaro

Forrester

Raghu

. Drug therapy for treatment of idiopathic pulmonary fibrosis: a systematic review and network meta-analysis. Value in Health. 2016;149(3):755–766.doi:10.1016/j.jval.2015.03.983.

25.

Kamba

Mcdonald

. Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer. 2007;96(12):1788–1795. doi:10.1038/sj.bjc.6603813.

26.

Loveman

Copley

Scott

. Comparing new treatments for idiopathic pulmonary fibrosis – a network meta-analysis. BMC Pulm Med. 2015;15(1):37. doi:10.1186/s12890-015-0034-y.

27.

Canestaro

Forrester

Raghu

. Drug treatment of idiopathic pulmonary fibrosis: a systematic review and network meta-analysis. Chest. 2016;149(3):756–766. doi:10.1016/j.chest.2015.11.013.

28.

Micromedex Solutions. Red Book 2017. Ann Arbor, MI: Nintedanib. Truven Health Analytics.

29.

Micromedex Solutions. Red Book 2017. Ann Arbor, MI: Pirfenidone. Truven Health Analytics.

30.

Loveman

Copley

Colquitt

. The effectiveness and cost-effectiveness of treatments for idiopathic pulmonary fibrosis: systematic review, network meta-analysis and health economic evaluation. BMC Pharmacol Toxicol. 2014;15:63.

31.

Rinciog

Watkins

Chang

. A cost-effectiveness analysis of nintedanib in idiopathic pulmonary fibrosis in the UK. PharmacoEconomics. 2017;35(4):479–491. doi:10.1007/s40273-016-0480-2

32.

Ogura

Taniguchi

Azuma

. Safety and pharmacokinetics of nintedanib and pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J. 2015;45(5):1382–1392.

33.

Hagmeyer

Treml

Priegnitz

. Successful concomitant therapy with pirfenidone and nintedanib in idiopathic pulmonary fibrosis: a case report. Respiration. 2016;91(4):327–332. doi:10.1159/000444690.

34.

Hoffmann-La Roche. Safety and Tolerability Study of Pirfenidone in Combination With Nintedanib in Participants With Idiopathic Pulmonary Fibrosis (IPF). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2016. https://clinicaltrials.gov/ct2/show/NCT02598193. NLM Identifier: NCT02598193. Accessed September 9, 2016.

35.

Boehringer Ingelheim. Safety, Tolerability and PK of Nintedanib in Combination With Pirfenidone in IPF. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2015. https://clinicaltrials.gov/ct2/show/NCT02579603. NLM Identifier: NCT02579603. Accessed September 9, 2016.

36.

Boehringer Ingelheim. Safety and PK Study of BIBF 1120 in Japanese Patients With IPF: Follow up Study From 1199.31(NCT01136174). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2011. https://clinicaltrials.gov/ct2/show/NCT01417156. NLM Identifier: NCT01417156. Accessed September 9, 2016.

37.

Boehringer Ingelheim. Efficacy and Safety of Nintedanib When Co-administered With Sildenafil in Idiopathic Pulmonary Fibrosis Patients With Advanced Lung Function Impairment. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2016. https://clinicaltrials.gov/ct2/show/NCT02802345. NLM Identifier: NCT02802345. Accessed September 9, 2016.

38.

Milger

Kneidinger

Neurohr

. Switching to nintedanib after discontinuation of pirfenidone due to adverse events in IPF. Eur Respir J. 2015;46(4):1217–1221. doi:10.1183/13993003.00584-2015.

39.

Bonella

Kreuter

Hagmeyer

. Insights from the German Compassionate Use Program of Nintedanib for the treatment of Idiopathic Pulmonary Fibrosis. Respiration. 2016;92(2):98–106. doi:10.1159/000448288.

40.

Hughes

Toellner

Morris

. Real world experiences: Pirfenidone and Nintedanib are effective and well tolerated treatments for Idiopathic Pulmonary Fibrosis. J Clin Med. 2016;5(9):78. doi:10.3390/jcm5090078.

41.

Boehringer Ingelheim. Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2012. https://clinicaltrials.gov/ct2/show/NCT01619085. NLM Identifier: NCT 01619085. Accessed September 9, 2016.

42.

Galli

Pandya

Vega-Olivo

. Pirfenidone and nintedanib for pulmonary fibrosis in clinical practice: tolerability and adverse drug reactions. Respirology. 2017;22(6):1171–1178. doi:10.1111/resp.13024.